Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308996650> ?p ?o ?g. }
- W4308996650 abstract "Abstract Bladder cancer is a major and fatal urological disease. Cisplatin is a key drug for the treatment of bladder cancer, especially in muscle-invasive cases. In most cases of bladder cancer, cisplatin is effective; however, resistance to cisplatin has a significant negative impact on prognosis. Thus, a treatment strategy for cisplatin-resistant bladder cancer is essential to improve the prognosis. In this study, we established a cisplatin-resistant (CR) bladder cancer cell line using a urothelial carcinoma cell line (UM-UC-3 cells). We screened for potential targets in CR cells and found that claspin (CLSPN) was overexpressed. CLSPN mRNA knockdown revealed that CLSPN had a role in cisplatin resistance in CR cells. In our previous study, we identified human leukocyte antigen (HLA)-A*02:01-restricted CLSPN peptide by HLA ligandome analysis. Thus, we generated a CLSPN peptide-specific cytotoxic T lymphocyte (CTL) clone that recognized CR cells at a higher level than wild-type UM-UC-3 cells. These findings indicate that CLSPN is a driver of cisplatin resistance and CLSPN peptide-specific immunotherapy may be effective for cisplatin-resistant cases." @default.
- W4308996650 created "2022-11-20" @default.
- W4308996650 creator A5000123851 @default.
- W4308996650 creator A5001403023 @default.
- W4308996650 creator A5003008239 @default.
- W4308996650 creator A5014986743 @default.
- W4308996650 creator A5020825623 @default.
- W4308996650 creator A5020934544 @default.
- W4308996650 creator A5023078180 @default.
- W4308996650 creator A5037167618 @default.
- W4308996650 creator A5039548485 @default.
- W4308996650 creator A5039611077 @default.
- W4308996650 creator A5047146482 @default.
- W4308996650 creator A5050081998 @default.
- W4308996650 creator A5053163842 @default.
- W4308996650 creator A5054298664 @default.
- W4308996650 creator A5055604300 @default.
- W4308996650 creator A5061939029 @default.
- W4308996650 creator A5066775767 @default.
- W4308996650 creator A5072637751 @default.
- W4308996650 creator A5080652822 @default.
- W4308996650 creator A5088717199 @default.
- W4308996650 creator A5088836383 @default.
- W4308996650 date "2022-11-14" @default.
- W4308996650 modified "2023-10-05" @default.
- W4308996650 title "Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma" @default.
- W4308996650 cites W1508781039 @default.
- W4308996650 cites W1996507133 @default.
- W4308996650 cites W2027646537 @default.
- W4308996650 cites W2034244225 @default.
- W4308996650 cites W2035618305 @default.
- W4308996650 cites W2058172383 @default.
- W4308996650 cites W2058845478 @default.
- W4308996650 cites W2064390432 @default.
- W4308996650 cites W2075135229 @default.
- W4308996650 cites W2131030413 @default.
- W4308996650 cites W2135925682 @default.
- W4308996650 cites W2165864530 @default.
- W4308996650 cites W2201600912 @default.
- W4308996650 cites W2338992976 @default.
- W4308996650 cites W2588916311 @default.
- W4308996650 cites W2596889284 @default.
- W4308996650 cites W2767819563 @default.
- W4308996650 cites W2793859699 @default.
- W4308996650 cites W2809275164 @default.
- W4308996650 cites W2907897113 @default.
- W4308996650 cites W2917933808 @default.
- W4308996650 cites W3000119127 @default.
- W4308996650 cites W3006465944 @default.
- W4308996650 cites W3011714452 @default.
- W4308996650 cites W3024551702 @default.
- W4308996650 cites W3048201207 @default.
- W4308996650 cites W3087464965 @default.
- W4308996650 cites W3128646645 @default.
- W4308996650 cites W3163995648 @default.
- W4308996650 cites W3181789424 @default.
- W4308996650 cites W3195294034 @default.
- W4308996650 cites W3198864056 @default.
- W4308996650 cites W3215443002 @default.
- W4308996650 cites W4224881253 @default.
- W4308996650 cites W4296793503 @default.
- W4308996650 cites W4302303967 @default.
- W4308996650 cites W2891845043 @default.
- W4308996650 doi "https://doi.org/10.21203/rs.3.rs-2259361/v1" @default.
- W4308996650 hasPublicationYear "2022" @default.
- W4308996650 type Work @default.
- W4308996650 citedByCount "0" @default.
- W4308996650 crossrefType "posted-content" @default.
- W4308996650 hasAuthorship W4308996650A5000123851 @default.
- W4308996650 hasAuthorship W4308996650A5001403023 @default.
- W4308996650 hasAuthorship W4308996650A5003008239 @default.
- W4308996650 hasAuthorship W4308996650A5014986743 @default.
- W4308996650 hasAuthorship W4308996650A5020825623 @default.
- W4308996650 hasAuthorship W4308996650A5020934544 @default.
- W4308996650 hasAuthorship W4308996650A5023078180 @default.
- W4308996650 hasAuthorship W4308996650A5037167618 @default.
- W4308996650 hasAuthorship W4308996650A5039548485 @default.
- W4308996650 hasAuthorship W4308996650A5039611077 @default.
- W4308996650 hasAuthorship W4308996650A5047146482 @default.
- W4308996650 hasAuthorship W4308996650A5050081998 @default.
- W4308996650 hasAuthorship W4308996650A5053163842 @default.
- W4308996650 hasAuthorship W4308996650A5054298664 @default.
- W4308996650 hasAuthorship W4308996650A5055604300 @default.
- W4308996650 hasAuthorship W4308996650A5061939029 @default.
- W4308996650 hasAuthorship W4308996650A5066775767 @default.
- W4308996650 hasAuthorship W4308996650A5072637751 @default.
- W4308996650 hasAuthorship W4308996650A5080652822 @default.
- W4308996650 hasAuthorship W4308996650A5088717199 @default.
- W4308996650 hasAuthorship W4308996650A5088836383 @default.
- W4308996650 hasBestOaLocation W43089966501 @default.
- W4308996650 hasConcept C104317684 @default.
- W4308996650 hasConcept C121608353 @default.
- W4308996650 hasConcept C126322002 @default.
- W4308996650 hasConcept C143998085 @default.
- W4308996650 hasConcept C147483822 @default.
- W4308996650 hasConcept C147969180 @default.
- W4308996650 hasConcept C154317977 @default.
- W4308996650 hasConcept C167672396 @default.
- W4308996650 hasConcept C173396325 @default.
- W4308996650 hasConcept C202751555 @default.